Compare Las Vegas Sands Corp. (LVS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs TG Therapeutics Inc — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Las Vegas Sands Corp. is far larger — about 2.9× TG Therapeutics Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and TG Therapeutics Inc for 16 Days on average.
| LVS | TGTX | |
|---|---|---|
Market Cap | $23.38B | $8.16B |
Volume | 6,994,661 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $59.06 |
52-Week Low | $35.81 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $35.27B | $8.37B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 12.59% net margin and consistent revenue growth, reaching $13.02B in 2025. Recent earnings have been mixed, with a Q2 2026 miss after two prior beats. Analyst sentiment remains positive with a 59% buy rating and a $59.78 consensus price target, implying significant upside. The company maintains robust cash flow from operations of $3.02B in 2025.
The outlook for LVS is cautiously optimistic, driven by solid fundamentals and analyst confidence, but weighed by technical weakness and high debt levels. Investment opportunity lies in the substantial discount to price targets, while risks include leverage, Macao regulatory exposure, and volatile earnings. The stock's current valuation multiples, such as a P/E of 13.99, appear attractive if operational execution continues.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
